$93 Million is the total value of VHCP Management, LLC's 21 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 20.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DBV Technologies | $31,130,000 | -4.2% | 456,893 | 0.0% | 33.47% | +4.8% | ||
| HRTX | Heron Therapeutics Inc | $14,354,000 | -24.0% | 1,095,734 | 0.0% | 15.44% | -16.9% | |
| CHRS | Coherus Biosciences Inc | $8,600,000 | +5.1% | 305,505 | 0.0% | 9.25% | +14.9% | |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $7,312,000 | +64.9% | 1,155,104 | +14.9% | 7.86% | +80.4% |
| FLML | Avadel Pharmaceuticals | $5,195,000 | -16.2% | 500,000 | 0.0% | 5.59% | -8.4% | |
| RARX | New | Ra Pharmaceuticals | $3,532,000 | – | 232,500 | +100.0% | 3.80% | – |
| ADVM | Adverum Biotechnologies | $3,198,000 | -29.4% | 1,102,735 | 0.0% | 3.44% | -22.8% | |
| LPCN | Lipocine Inc | $3,128,000 | -17.5% | 849,921 | 0.0% | 3.36% | -9.8% | |
| CLCD | CoLucid Pharmaceuticals | $2,482,000 | -4.6% | 68,190 | 0.0% | 2.67% | +4.3% | |
| AXGT | Axovant Sciences Ltd | $2,287,000 | -11.3% | 184,110 | 0.0% | 2.46% | -3.0% | |
| OCRX | Buy | Ocera Therapeutics | $1,915,000 | -15.3% | 912,050 | +6.5% | 2.06% | -7.4% |
| ASND | Ascendis Pharma A/S | $1,822,000 | +0.7% | 90,000 | 0.0% | 1.96% | +10.1% | |
| EDGE | Edge Therapeutics Inc | $1,688,000 | +20.1% | 135,000 | 0.0% | 1.82% | +31.3% | |
| STML | Stemline Therapeutics Inc | $1,449,000 | -1.2% | 135,420 | 0.0% | 1.56% | +8.0% | |
| ADHD | Alcobra Ltd | $1,384,000 | -15.0% | 658,910 | 0.0% | 1.49% | -7.1% | |
| ABIO | ARCA biopharma Inc | $1,318,000 | +0.7% | 462,399 | 0.0% | 1.42% | +10.1% | |
| AKTX | Akari Therapeutics Plc | $1,115,000 | -17.3% | 158,352 | 0.0% | 1.20% | -9.6% | |
| CTMX | CytomX Therapeutics Inc | $706,000 | -29.9% | 64,200 | 0.0% | 0.76% | -23.3% | |
| BOLD | Audentes Therapeutics | $274,000 | +2.6% | 15,000 | 0.0% | 0.30% | +12.2% | |
| DNAI | ProNAI Therapeutics Inc | $84,000 | -17.6% | 56,056 | 0.0% | 0.09% | -10.0% | |
| AGLE | Aeglea BioTherapeutics | $26,000 | -31.6% | 6,000 | 0.0% | 0.03% | -24.3% | |
| RGNX | Exit | REGENXBIO Inc | $0 | – | -24,089 | -100.0% | -0.33% | – |
| ACHN | Exit | Achillion Pharmaceuticals Inc | $0 | – | -180,000 | -100.0% | -1.43% | – |
| BGNE | Exit | BeiGene Ltd | $0 | – | -51,000 | -100.0% | -1.54% | – |
| ZFGN | Exit | Zafgen Inc | $0 | – | -602,114 | -100.0% | -1.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.